News

According to results from a phase 3 trial presented at the 2024 SGO Annual Meeting on Women’s Cancer, the addition of atezolizumab to first-line bevacizumab and chemotherapy improved progression-free survival, overall survival, and objective...

Tisotumab vedotin demonstrated a statistically significant and clinically meaningful improvement in overall survival, progression-free survival, and objective response rate among patients with second-/third-line recurrent or metastatic...

The FDA granted accelerated approval for zanubrutinib with obinutuzumab treatment for patients with relapsed or refractory follicular lymphoma, following 2 or more lines of systemic therapy.

A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.

According to a retrospective study, patients who experienced a dose reduction while on cabozantinib for metastatic renal cell carcinoma had improved overall survival and time to treatment failure.

On March 6, 2024, the FDA approved inotuzumab ozogamicin for pediatric patients with relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.

According to a phase 3 trial, adding daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy yielded beneficial outcomes among transplantation-eligible patients with newly diagnosed multiple...

Orly Leiva, MD, and colleagues examined cardiovascular outcomes for patients with myeloproliferative neoplasms, highlighting increased risks for patients with myelofibrosis.

The FDA has approved belzutifan, an HIF-2α inhibitor, for the treatment of advanced kidney cancer, based on promising results from the phase 3 LITESPARK-005 trial led by Dana-Farber researchers.

Two leading oncology care organizations, the National Cancer Care Alliance (NCCA) and Quality Clinical Cancer Associates (QCCA), have joined forces to create ONCare Alliance, LLC.